AtriCure, Inc. Aktie News

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator in chirurgischen Behandlungen und Therapien für Vorhofflimmern (Afib), das Management des linken Vorhofohrs (LAA) und die Behandlung postoperativer Schmerzen, gab heute bekannt, dass das Unternehmen an der bevorstehenden Wells Fargo Health Care Conference 2026 teilnehmen wird. Das Management von AtriCure wird a...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator in chirurgischen Behandlungen und Therapien für Vorhofflimmern (Afib), Management des linken Vorhofohrs (LAA) und Schmerzmanagement nach Operationen, gab heute die Finanzergebnisse für das zweite Quartal 2026 bekannt. „Unser Team erzielte im zweiten Quartal gesundes Wachstum und einen deutlichen Anstieg der Pro...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to parti...

AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. “Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined execution and incr...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to partic...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tue...